Company Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.
The company is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Paula Ragan |
Contact Details
Address: 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 United States | |
| Phone | 857 529 8300 |
| Website | x4pharma.com |
Stock Details
| Ticker Symbol | XFOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501697 |
| CUSIP Number | 98420X103 |
| ISIN Number | US98420X1037 |
| Employer ID | 27-3181608 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paula Ragan Ph.D. | Chief Executive Officer, President and Director |
| Adam S. Mostafa | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Richard Peters M.D., Ph.D. | Founder |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Keith T. Flaherty M.D. | Founder and Member of Corporate Advisory Board |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer |
| Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research |
| Mark Baldry M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 144 | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 144 | Filing |
| Oct 7, 2024 | 144 | Filing |